FDA approves first treatment for chronic hepatitis delta virus infection

06 Jun 2026, 00:20 · Medical Xpress

by Lori Solomon

edited by Sadie Harley, reviewed by Andrew Zinin

Sadie Harley

Scientific Editor

Meet our editorial team
Behind our editorial process

Andrew Zinin

Lead Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

reputable news agency

proofread

The GIST Add as preferred source

The U.S. Food and Drug Administration has approved Hepcludex (bulevirtide‐gmod) injection to treat chronic hepatitis delta virus (HDV) infection in adults without cirrhosis or compensated cirrhosis. Approval of Hepcludex was granted to Gilead Sciences.

Hepcludex received priority review and was approved under the Accelerated Approval pathway. It also received Breakthrough Therapy Designation and Orphan‐Drug Designation. There is a boxed warning that discontinuation of Hepcludex may result in severe acute exacerbations of HDV and hepatitis B virus infection.

The approval was based on results from a Phase III trial in which participants were randomly assigned to immediate treatment with Hepcludex (8.5 mg once daily for 144 weeks) or to delayed treatment following a 48‐week observational period.

At week 48, the rate of undetectable HDV RNA (less than the lower limit of quantification of 50 IU/mL) was 20% in the Hepcludex group versus 0% in the delayed treatment group. At weeks 96 and 144, the rate of undetectable HDV RNA increased to 36 and 50%, respectively, in the Hepcludex group.

"Today's approval fills a critical gap in care for patients with chronic HDV infection, who until now have had no FDA‐approved therapies available," Wendy Carter, D.O., from the FDA Center for Drug Evaluation and Research, said in a statement.

"For individuals living with this chronic viral infection, this new treatment option offers hope in managing a disease that can rapidly progress to serious liver complications."

Key medical concepts

bulevirtideClinical Trials, Phase III as TopicHepatitis B

Clinical categories

Infectious diseasesGastroenterology Who's behind this story?

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: FDA approves first treatment for chronic hepatitis delta virus infection (2026, June 5) retrieved 6 June 2026 from https://medicalxpress.com/news/2026-06-fda-treatment-chronic-hepatitis-delta.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.